Anti-MMS21 antibody (ab241347)
Key features and details
- Rabbit polyclonal to MMS21
- Suitable for: IP
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-MMS21 antibody
See all MMS21 primary antibodies -
Description
Rabbit polyclonal to MMS21 -
Host species
Rabbit -
Tested applications
Suitable for: IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human MMS21 aa 197-247. The exact sequence is proprietary. (NP_775956.1).
Database link: Q96MF7 -
Positive control
- IP: HeLa whole cell lysate.
-
General notes
ab241347 has not performed satisfactorily when used for WB of MMS21 in crude preparations (e.g. whole cell lysate). This antibody can be used for WB of enriched (e.g. immunoprecipitated) sources of MMS21.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8 -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab241347 was affinity purified using an epitope specific to MMS21 immobilized on solid support. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab241347 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at 2-10 µg/mg of lysate.
|
Notes |
---|
IP
Use at 2-10 µg/mg of lysate. |
Target
-
Function
E3 SUMO-protein ligase component of the SMC5-SMC6 complex, a complex involved in DNA double-strand breaks by homologous recombination. The complex may promote sister chromatid homologous recombination by recruiting the SMC1-SMC3 cohesin complex to double-strand breaks. Acts as a E3 ligase mediating SUMO attachment to various proteins such as SMC6L1 and TRAX, and maybe the cohesin components RAD21 and STAG2. SUMO protein-ligase activity is required for the prevention of DNA damage-induced apoptosis by facilitating DNA repair. -
Pathway
Protein modification; protein sumoylation. -
Sequence similarities
Belongs to the NSE2 family.
Contains 1 SP-RING-type zinc finger. -
Post-translational
modificationsSumoylated, possibly via autosumoylation. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 286053 Human
- SwissProt: Q96MF7 Human
- Unigene: 388297 Human
-
Alternative names
- C8orf36 antibody
- E3 SUMO-protein ligase NSE2 antibody
- hMMS21 antibody
see all
Images
-
MMS21 was immunoprecipitated from HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg per IP reaction; 20% of IP loaded). ab241347 used for IP at 6 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab241347 at 1 µg/ml.
Lane 1: ab241347 IP in HeLa whole cell lysate.
Lane 2: Control IgG in HeLa whole cell lysate.Detection: Chemiluminescence with an exposure time of 3 minutes.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab241347 has not yet been referenced specifically in any publications.